Study design. (A) Cohorts of 3 to 6 patients received intravenous (IV) infusions of obinutuzumab weekly for 4 weeks, with tumor assessment at week 13. (B) Cohort doses were escalated in a standard 3 + 3 design up to 2000 mg or until the MTD was reached. For each cohort, the first infusion was ∼ 50% to 60% of the cohort dose. (C) Patients who had a complete or partial response (or stable disease and clinical benefit) were eligible to enter a 2-year maintenance therapy regimen of single-agent obinutuzumab once every 3 months, for a maximum of 8 infusions, beginning 3 months after the last induction infusion. The first administration of maintenance therapy was initiated 3 months after the last infusion of induction obinutuzumab.